Dose of Reality

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART I

Dec 28, 2021

Part I: Price-Gouging An Unproven Treatment, Setting Out-of-Control Launch Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART II

Dec 28, 2021

Part II: Pushing Debunked Innovation Rhetoric to Oppose Rx Solutions Despite Read More

DOSE OF REALITY: BIG PHARMA’S YEAR OF BAD BEHAVIOR — PART III

Dec 28, 2021

Part III: Big Pharma Maintains Price-Hiking, Patent-Gaming Business-As-Usual Read More

DOSE OF REALITY: OVERSIGHT REPORT EXPOSES BIG PHARMA’S EGREGIOUS PRICING & ANTI-COMPETITIVE TACTICS — DEBUNKS INNOVATION RHETORIC

Dec 12, 2021

Investigation Finds Big Pharma Hiked Prices More Than 250 Times On Just 12 Top Read More

DOSE OF REALITY: LAWMAKERS TO PROBE BIG PHARMA PATENT ABUSE AS INNOVATION EXCUSES CRUMBLE

Jul 13, 2021

U.S. Senate Judiciary Subcommittee Hearing Tuesday Will Build on Momentum for Read More

DOSE OF REALITY: HUMIRA: A CASE STUDY IN BIG PHARMA GREED

May 17, 2021

AbbVie CEO Headed for Capitol Hill to Answer for Indefensible Anti-Competitive Read More

DOSE OF REALITY: BIG PHARMA’S PRICING PRACTICES DRIVE CRISIS OF AFFORDABILITY FOR AMERICA’S CANCER PATIENTS

Apr 15, 2021

Drug Companies Repeatedly Hike Prices and Set Out-of-Control Launch Prices on Read More

DOSE OF REALITY: BIG PHARMA TO TESTIFY ON COVID-19 VACCINES AGAINST BACKDROP OF PANDEMIC PRICE HIKES AND BIG TIME PROFITS

Feb 22, 2021

Brand Name Drug Executives Should Commit to Affordable Pricing on COVID-19 Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 31, 2020

Part IV: Escalating Assault on 340B Program for Providers Serving America’s Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 30, 2020

Part III: Angling to Price-Gouge American Public on COVID-19 Treatments Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 29, 2020

Part II: Gaming the System to Undermine Competition at the Expense of American Read More

“DOSE OF REALITY” BIG PHARMA’S YEAR OF BAD BEHAVIOR

Dec 28, 2020

Part I: Sticking with Price-Hiking “Business-as-Usual” During Pandemic Read More